MX2010001171A - Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico. - Google Patents

Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.

Info

Publication number
MX2010001171A
MX2010001171A MX2010001171A MX2010001171A MX2010001171A MX 2010001171 A MX2010001171 A MX 2010001171A MX 2010001171 A MX2010001171 A MX 2010001171A MX 2010001171 A MX2010001171 A MX 2010001171A MX 2010001171 A MX2010001171 A MX 2010001171A
Authority
MX
Mexico
Prior art keywords
disrupted
conditions
kncq
reducing symptoms
dopaminergic system
Prior art date
Application number
MX2010001171A
Other languages
English (en)
Spanish (es)
Inventor
Henriette Husum Bak-Jensen
Klaus Peter Hertel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010001171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2010001171A publication Critical patent/MX2010001171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010001171A 2007-08-01 2008-07-31 Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico. MX2010001171A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95330807P 2007-08-01 2007-08-01
DKPA200701110 2007-08-01
PCT/DK2008/050191 WO2009015667A1 (en) 2007-08-01 2008-07-31 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Publications (1)

Publication Number Publication Date
MX2010001171A true MX2010001171A (es) 2010-03-01

Family

ID=39810209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001171A MX2010001171A (es) 2007-08-01 2008-07-31 Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.

Country Status (17)

Country Link
US (1) US20100256145A1 (OSRAM)
EP (1) EP2185149A1 (OSRAM)
JP (1) JP2011513196A (OSRAM)
KR (1) KR20100050502A (OSRAM)
CN (1) CN101790374A (OSRAM)
AR (1) AR070513A1 (OSRAM)
AU (1) AU2008281112A1 (OSRAM)
BR (1) BRPI0814180A2 (OSRAM)
CA (1) CA2694887A1 (OSRAM)
CL (1) CL2008002273A1 (OSRAM)
EA (1) EA201070189A1 (OSRAM)
MX (1) MX2010001171A (OSRAM)
NZ (1) NZ582942A (OSRAM)
TW (1) TW200920350A (OSRAM)
UA (1) UA97847C2 (OSRAM)
WO (1) WO2009015667A1 (OSRAM)
ZA (1) ZA201000129B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CN102014909B (zh) * 2008-02-21 2013-03-13 田边三菱制药株式会社 口服用固体制剂
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
EP2408747A1 (en) 2009-03-17 2012-01-25 NeuroSearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
JPWO2010137689A1 (ja) * 2009-05-29 2012-11-15 アステラス製薬株式会社 注意欠陥／多動性障害新規予防用及び／又は治療用医薬組成物
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
CN102971307A (zh) 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
AU2014360743C1 (en) * 2013-12-02 2021-01-28 Chemocentryx, Inc. CCR6 compounds
MX373603B (es) * 2014-10-24 2020-05-26 Ono Pharmaceutical Co Activador de canales de kcnq2-5.
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
CN109641836A (zh) 2016-06-10 2019-04-16 赛弗卢尔生命科学公司 氟化的2-氨基-4-(取代的氨基)苯基氨基甲酸酯衍生物
PL3730487T3 (pl) 2016-06-13 2022-08-16 Gilead Sciences, Inc. Pochodne azetydyny jako modulatory fxr (nr1h4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
EP4241843B1 (en) 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
TWI788325B (zh) * 2018-02-21 2023-01-01 丹麥商Ｈ 朗德貝克公司 作為Ｋｖ７鉀通道開放劑的醇衍生物
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN108707087B (zh) 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN108863893A (zh) * 2018-07-09 2018-11-23 湖南博隽生物医药有限公司 二氢吲哚类衍生物及其在药物中的应用
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
IL290193B2 (en) 2019-08-02 2024-12-01 H Lundbeck As Alcohol derivatives as kv7 potassium channel openers
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
GEAP202415942A (en) 2019-11-08 2024-10-28 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
KR102643653B1 (ko) * 2020-11-13 2024-03-06 기초과학연구원 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
GEAP202416348A (en) 2021-02-09 2024-01-10 Xenon Pharmaceuticals Inc Methods and uses for treating anhedonia
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
CN118026880A (zh) * 2022-11-11 2024-05-14 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
TW202521516A (zh) * 2023-08-17 2025-06-01 加拿大商再諾製藥公司 氮雜環庚烷及吡咯啶化合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (OSRAM) * 1990-07-14 1993-08-14 Asta Medica Ag
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
DE60037321D1 (de) * 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
MXPA03007397A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
US6831080B2 (en) * 2001-05-31 2004-12-14 Bristol-Myers Squibb Company Cinnamide derivatives as KCNQ potassium channel modulators
AU2003294442A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
PT1578740E (pt) * 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
JP2006523196A (ja) * 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規ｋｃｎｑチャネルを調節する化合物及びその医薬用途
JP2006520333A (ja) * 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
MXPA05010000A (es) * 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
US7812020B2 (en) * 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
EP1937653A1 (en) * 2005-09-09 2008-07-02 H.Lundbeck A/S Pyrimidine derivatives and their use as kcnq potassium channels openers
AU2007214128B2 (en) * 2006-02-07 2012-05-17 H. Lundbeck A/S Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms

Also Published As

Publication number Publication date
BRPI0814180A2 (pt) 2015-01-27
AU2008281112A1 (en) 2009-02-05
TW200920350A (en) 2009-05-16
WO2009015667A1 (en) 2009-02-05
CA2694887A1 (en) 2009-02-05
US20100256145A1 (en) 2010-10-07
JP2011513196A (ja) 2011-04-28
CN101790374A (zh) 2010-07-28
ZA201000129B (en) 2011-04-28
UA97847C2 (ru) 2012-03-26
KR20100050502A (ko) 2010-05-13
EP2185149A1 (en) 2010-05-19
EA201070189A1 (ru) 2010-08-30
NZ582942A (en) 2011-09-30
CL2008002273A1 (es) 2009-07-17
AR070513A1 (es) 2010-04-14

Similar Documents

Publication Publication Date Title
MX2010001171A (es) Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.
WO2009012242A3 (en) Sodium channel inhibitors
EA201490088A1 (ru) Соединения, ингибирующие металлоферменты
EA201490038A1 (ru) Соединения, ингибирующие металлоферменты
AU2016255707A8 (en) Uses of cannabidiol for treatment of infantile spasms
PH12013502623A1 (en) Metalloenzyme inhibitor compounds
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
EA201491385A1 (ru) Соединения, ингибирующие металлоферменты
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
HK1213291A1 (zh) 用於治療胱氨酸尿症的胱硫醚β合酶
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
GB2475660A (en) Methods and kits for treating cluster headache disorders
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
NO20083838L (no) Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
MX2020000611A (es) Composiciones y metodos para tratar trastornos relacionados con el estres.
MX2010007810A (es) Coposicion que contiene capsicum para tratar un trastorno de la piel.
MX2010004814A (es) Metodos para tratar esclerodermia.
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2011028890A3 (en) Compositions and methods for treatment of neuropathic pain
WO2013049272A3 (en) Composition and method for treatment of symptoms associated with various skin conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal